79% of consumers would consider genetic testing to limit drug side effects

Forty percent of consumers think physicians can lower patients' drug side effect risks through genetic testing, according to a Wamberg Genomic consumer survey.

The results consider survey responses fielded in October from 536 U.S. consumers between the ages of 26 and 64.

Here are three additional findings from the survey.

1. Seventy-nine percent of respondents would consider genetic testing, or pharmacogenomics, to lower potential drug side effect risks.

2. When asked, "If you were offered free genetic testing to limit the risk of drug side effects, would you want to get this testing now, whether or [not] you are currently on medications?" respondents answered the following:

  • Yes                      49 percent
  • Considering         30 percent
  • Not sure               13 percent
  • No                          8 percent

3. Thirty-three percent of respondents had undergone genetic testing. Of those tested, 52 percent found the results useful, according to the survey. 

More articles on supply chain:
6 medical groups to Congress: We need a 'comprehensive strategy' for critical drug shortages
AHA urges FDA to address saline bag shortage 
5 recent pharma layoffs

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months